NEWS
Outscale, first French cloud provider,
gets Preferred Partner status
O
utscale, a French cloud computing services provider (IaaS) and
strategic partner to Dassault Systèmes, has been made Preferred
Partner by the global NVIDIA Partner Network (NPN).
The NVIDIA NPN programme approves cloud service providers who
are highly skilled in cloud-based graphics services. By joining the
programme, Outscale offers ground-breaking solutions to the cloud’s
main challenges including 3D features, Big Data and machine
learning. In addition to cloud services for commodities and the
general public, Outscale provides cloud-based NVIDIA GPU solutions,
thereby boosting graphics and calculating power (VDI/3D/Big Data/
machine learning), which are also included in cloud appliance such as
TINA OnPremise.
David Chassan, Outscale Chief Communications Officer, said: “We
are thrilled we made the grade to be included on NVIDIA NPN’s
world programme and that Outscale is the first
independent cloud services provider to break
into this exclusive community. Working with
one of the most innovative market players is
genuine recognition for us. The partnership will
allow us to provide world-class feature-packed
solutions for private, hybrid and public clouds.”
Serge Palaric, NVIDIA VP Enterprise Southern
Europe, added: “Outscale is well-known for
helping clients rollout complex IT projects that
effectively meet their operational needs. The
NPN programme is designed to help partners,
including us, boost sales growth and take on
new markets.”
//////////////////
Voluntis and Roche Pharma France
utilise digital therapeutics
broaden their collaboration by extending
ZEMY to all solid tumours, through Voluntis’
Theraxium platform. Voluntis and Roche
have therefore expanded their licensing
and co-development agreement, in which
Voluntis acts as the legal manufacturer
of ZEMY, heading its technology and
regulatory development and Roche leads
the clinical evaluation process and the
future commercialisation of the solution to
oncology centres.
V
oluntis and Roche Pharma France have
announced that important milestones
have been reached in the development of
ZEMY, a digital therapeutic developed by
Roche Pharma France in partnership with
Voluntis since 2015. ZEMY aims to improve
care support for breast cancer patients. Its
co-construction with various stakeholders
(patients, healthcare professionals, etc.)
18
INTELLIGENTCIO
has been critical in developing its medical
algorithms and validating its ease of use.
A multi-centre clinical study has been
initiated to evaluate adherence to the ZEMY
solution as well as potential improvement
in patients’ quality of life. Voluntis and
Roche will seek regulatory clearance for
this innovative software medical device.
In addition, both partners have agreed to
“We have mobilised our complementary
expertise to co-develop a solution that could
help the self-management of symptoms,
while allowing the patient to stay in touch
with their care team,” said Pierre Leurent,
CEO of Voluntis. “We are very happy to
expand our collaboration with Roche, the
world leader in oncology, by extending
ZEMY to all solid cancers. This partnership
rigorously demonstrates how a digital
therapeutic can benefit patient care.”
www.intelligentcio.com